Mark A. Schroeder
Washington University in St. Louis
Internal medicineSurgeryOncologyAdverse effectImmunologyIn vivoMultiple myelomaTemozolomideHematopoietic stem cell transplantationGliomaMyeloid leukemiaGraft-versus-host diseaseBone marrowStem cellTransplantationCancer researchMedicineBiologyGastroenterologyPharmacology
Publications 258
#1Karishma Rajani (Mayo Clinic)H-Index: 8
#2Ian Olson (Mayo Clinic)H-Index: 1
Last. Masum RahmanH-Index: 2
view all 13 authors...
BACKGROUND Microdialysis is a well validated sampling technique that can be used for pharmacokinetic studies of oncological drugs targeting the central nervous system. This technique has also been applied to evaluate tumor metabolism and identify pharmacodynamic biomarkers of drug activity. Despite the potential utility of microdialysis for therapeutic discovery, variability in tumor size and location hamper routine use of microdialysis as a preclinical tool. Quantitative validation of microdial...
#1Oren Pasvolsky (TAU: Tel Aviv University)H-Index: 9
#2Moshe Yeshurun (TAU: Tel Aviv University)H-Index: 21
Last. Robert Peter Gale (Imperial College London)H-Index: 137
view all 30 authors...
The role of maintenance therapy after high-dose chemotherapy and first autologous transplantation in multiple myeloma (MM) is well established. We explored the effect of maintenance therapy on outcomes after salvage second autologous hematopoietic cell transplant (AHCT2) using the Center for International Blood and Marrow Transplant Research registry. Outcomes of interest included non-relapse mortality (NRM), relapse/progression (REL), progression-free and overall survival (PFS, OS). Of 522 pati...
#1Jingyu Xiang (WashU: Washington University in St. Louis)H-Index: 8
#2Min Shi (WashU: Washington University in St. Louis)H-Index: 35
Last. Shamim A. Mollah (WashU: Washington University in St. Louis)H-Index: 7
view all 11 authors...
Mobilized peripheral blood has become the primary source of hematopoietic stem cells for both autologous and allogeneic stem cell transplantation. Granulocyte Colony-Stimulating Factor (G-CSF) is currently the standard agent used in the allogeneic setting. Despite the high mobilization efficacy in most donors, G-CSF requires 4-5 days of daily administration, and a small percentage of the donors fail to mobilize an optimal number of stem cells necessary for a safe allogeneic stem cell transplant....
#1Eric Huselton (URMC: University of Rochester Medical Center)H-Index: 4
#2Michael P. Rettig (WashU: Washington University in St. Louis)H-Index: 26
Last. Mark A. Schroeder (WashU: Washington University in St. Louis)H-Index: 43
view all 13 authors...
Abstract null null Leukemia stem cells utilize cell adhesion molecules like CXCR4/CXCL12 to home to bone marrow stromal niches where they are maintained in a dormant, protected state. Dociparstat sodium (DSTAT, CX-01) is a low anticoagulant heparin with multiple mechanisms of action, including inhibition of the CXCR4/CXCL12 axis, blocking HMGB1, and binding platelet factor 4 (PF-4). We conducted a pilot study adding DSTAT to azacitidine for patients with AML or MDS unresponsive to or relapsed af...
#1Sameem Abedin (MCW: Medical College of Wisconsin)H-Index: 11
#2Nahid Rashid (UW: University of Washington)
Last. Mehrdad Hefazi (Mayo Clinic)H-Index: 11
view all 20 authors...
Ruxolitinib for steroid-refractory acute graft-versus-host disease (SR-aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib-resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in ...
1 CitationsSource
#1Danielle M. Burgenske (Mayo Clinic)H-Index: 2
#2Surabhi Talele (UMN: University of Minnesota)H-Index: 1
Last. Gautham Gampa (UMN: University of Minnesota)H-Index: 6
view all 22 authors...
BACKGROUND Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts. METHODS Mice bearing intracranial tumors received lisavanbulin +/- RT +...
#1Lawrence Liu (SLU: Saint Louis University)
#2Mark Fiala (SLU: Saint Louis University)
Last. Mark A. Schroeder (WashU: Washington University in St. Louis)H-Index: 43
view all 9 authors...
Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center's data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma (n = 18),...
#1Yngvar Fløisand (Oslo University Hospital)H-Index: 17
#2Mark A. Schroeder (WashU: Washington University in St. Louis)H-Index: 43
Last. Andrejus Parfionovas (Millennium Pharmaceuticals)H-Index: 2
view all 14 authors...
Steroid-refractory (SR) acute graft-versus-host disease (aGvHD) remains a significant complication after allogeneic hematopoietic cell transplantation. Systemic corticosteroids are first-line therapy for aGvHD, but apart from ruxolitinib, there are no approved treatments for SR aGvHD. Vedolizumab is approved for treatment of ulcerative colitis and Crohn's disease, and may be effective for treatment of SR intestinal aGvHD. We conducted a phase 2a trial (NCT02993783) to evaluate the clinical effic...
#1Mark A. Fiala (WashU: Washington University in St. Louis)H-Index: 20
#2Justin King (WashU: Washington University in St. Louis)H-Index: 8
Last. Tanya M. Wildes (WashU: Washington University in St. Louis)H-Index: 26
view all 9 authors...
#1Sani H. Kizilbash (Mayo Clinic)H-Index: 10
#2Shiv K. Gupta (Mayo Clinic)H-Index: 8
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 67
view all 13 authors...
Tesevatinib is a potent oral brain penetrant EGFR inhibitor currently being evaluated for glioblastoma therapy. Tesevatinib distribution was assessed in wild-type (WT) and Mdr1a/b(-/-)Bcrp(-/-) triple knockout (TKO) FVB mice after dosing orally or via osmotic minipump; drug-tissue binding was assessed by rapid equilibrium dialysis. Two hours after tesevatinib dosing, brain concentrations in WT and TKO mice were 0.72 and 10.03 µg/g, respectively. Brain-to-plasma ratios (Kp) were 0.53 and 5.73, re...
1 CitationsSource